Register now to represent the very best of British innovation in a thriving market
8 – 12 February 2015
Register now to join UK Trade & Investment’s Oncology market visit to India. This mission will focus on India’s two leading cities in the field of Oncology – Bangalore and Mumbai – and coincide with India’s flagship Biotechnology event,Bangalore India Bio.

Led by Business Ambassador, Harriet Fear, the mission will start in Bangalore – considered the hub for drug discovery and research in India – before moving to Mumbai on the 3rd day.

Here, the delegation will link with Healthcare UK’s activity during the same period, culminating in a high profile, collective presence to promote the Best of British in Life Sciences, Healthcare and UK innovation.

Mission Benefits

• Meet with 300+ Pharma, Biotech and Healthcare companies, including company visits to key organisations: Tata Memorial and Cipla in Mumbai, Biocon and NCBS in Bangalore
• Be a part of the UK presence at India’s flagship Biotechnology event,Bangalore India Bio
• Take part in Drug Discovery and Innovation workshops, key seminar sessions, and exclusive networking events, including the Best of
• British reception in Mumbai with Healthcare UK’s mission delegation
• Your mission presence will be extended via the mission brochure, as well as with local media and press coverage

Is it for me?

This mission is suited to organisations working on Oncology or in drug discovery, particularly those with interest in:

• Research and development
• Platform technologies
• Genome sequencing
• Medical devices
• Screening and diagnostics

Find out more:

W: www.events.ukti.gov.uk/india-oncology–drug-discovery-mission/
E: IndiaOncology@uktieventspecialist.co.uk
T: 020 7034 4848

For logistical support, such as hotel options and visa contacts, please email the above address for further information.

India is the world’s third largest country affected by new cases of cancer, after the US and China.

The key areas of focus in Oncology in India are breast cancer, colorectal cancer, lung cancer, NHL and prostate cancer.

The market is expected to grow at a compounded rate of 6.5% per annum to $240 million by 2018.